Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Other financing activities (2016 - 2019)

Sunshine Biopharma filings provide 7 years of Other financing activities readings, the most recent being $7590.0 for Q4 2019.

  • On a quarterly basis, Other financing activities fell 98.92% to $7590.0 in Q4 2019 year-over-year; TTM through Dec 2020 was $7590.0, a N/A change, with the full-year FY2018 number at $676100.0, up 58.19% from a year prior.
  • Other financing activities hit $7590.0 in Q4 2019 for Sunshine Biopharma, up from -$7590.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $705568.0 in Q4 2018 to a low of -$411566.0 in Q2 2018.
  • Median Other financing activities over the past 5 years was $82000.0 (2016), compared with a mean of $137307.1.
  • The widest YoY moves for Other financing activities: up 3261.81% in 2018, down 743.07% in 2018.
  • Sunshine Biopharma's Other financing activities stood at $116500.0 in 2015, then soared by 142.75% to $282800.0 in 2016, then crashed by 120.05% to -$56700.0 in 2017, then skyrocketed by 1344.39% to $705568.0 in 2018, then crashed by 98.92% to $7590.0 in 2019.
  • The last three reported values for Other financing activities were $7590.0 (Q4 2019), -$7590.0 (Q2 2019), and $705568.0 (Q4 2018) per Business Quant data.